Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 159.88M | 148.93M | 133.01M | 127.79M | 111.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 159.88M | 148.93M | 133.01M | 127.79M | 111.59M |
| Cost of Revenue | 28.81M | 28.26M | 25.54M | 23.42M | 23.02M |
| Gross Profit | 131.08M | 120.67M | 107.47M | 104.36M | 88.57M |
| SG&A Expenses | 96.33M | 74.13M | 61.91M | 63.29M | 57.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.05M | 153.50M | 130.41M | 132.77M | 121.77M |
| Operating Income | -63.16M | -4.57M | 2.60M | -4.99M | -10.18M |
| Income Before Tax | -789.68M | -4.96M | 2.64M | -5.46M | -13.65M |
| Income Tax Expenses | 475.00K | 767.00K | -262.00K | 402.00K | 1.03M |
| Earnings from Continuing Operations | -790.16M | -5.73M | 2.91M | -5.86M | -14.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -790.16M | -5.73M | 2.91M | -5.86M | -14.68M |
| EBIT | -63.16M | -4.57M | 2.60M | -4.99M | -10.18M |
| EBITDA | -56.29M | 1.51M | 8.67M | 1.07M | -4.13M |
| EPS Basic | -13.43 | -0.11 | 0.06 | -0.12 | -0.30 |
| Normalized Basic EPS | -0.68 | -0.06 | 0.03 | -0.07 | -0.11 |
| EPS Diluted | -13.43 | -0.12 | 0.05 | -0.12 | -0.30 |
| Normalized Diluted EPS | -0.68 | -0.06 | 0.03 | -0.07 | -0.11 |
| Average Basic Shares Outstanding | 58.85M | 50.20M | 50.64M | 49.73M | 48.89M |
| Average Diluted Shares Outstanding | 58.85M | 50.20M | 56.99M | 49.73M | 48.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |